BofA Securities analyst Jason Gerberry raised the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $91.00 (from $82.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Form 8-K Intra-Cellular Therapies For: Apr 16April 16, 2024 4:41 PM Form 424B5 Intra-Cellular Therapies April 16, 2024 4:37 PM Intra-Cellular Therapies (ITCI) Announces Proposed $500M Share OfferingApril 16, 2024 4:07 PM Intra-Cellular Therapies Announces Proposed Public Offering of Common StockApril 16, 2024 4:06 PM Intra-Cellular Therapies (ITCI) Files Mixed ShelfApril 16, 2024 4:04 PM Form S-3ASR Intra-Cellular Therapies April 16, 2024 4:02 PM Intra-Cellular Therapies (ITCI) PT Raised to $90 at TD CowenApril 16, 2024 1:58 PM Midday movers: Morgan Stanley, UnitedHealth rise; Tesla fallsApril 16, 2024 9:01 AM Mizuho positive on Intra-Cellular Therapies (ITCI), 'potential for the stock to move even higher'April 16, 2024 8:40 AM Form 8-K Intra-Cellular Therapies For: Apr 16April 16, 2024 7:10 AM Intra-Cellular Therapies (ITCI) to Resume Trading at 7:30 a.m. April 16, 2024 7:06 AM Intra-Cellular Therapies (ITCI) Reports Positive Phase 3 Topline Results from Study 501April 16, 2024 7:01 AM Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive DisorderApril 16, 2024 7:00 AM Intra-Cellular Therapies (ITCI) Halted, News PendingApril 16, 2024 6:55 AM